Literature DB >> 7556242

Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa.

A C Başustaoğlu, H Gün, M A Saraçli, M Baysallar, T Haznedaroğlu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7556242     DOI： 10.1007/bf02114909

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  6 in total

1.  In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.

Authors:  D Voutsinas; T Mavroudis; A Avlamis; H Giamarellou
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

2.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

3.  Resistance to imipenem among selected gram-negative bacilli in the United States.

Authors:  R P Gaynes; D H Culver
Journal:  Infect Control Hosp Epidemiol       Date:  1992-01       Impact factor: 3.254

Review 4.  Imipenem.

Authors:  W C Hellinger; N S Brewer
Journal:  Mayo Clin Proc       Date:  1991-10       Impact factor: 7.616

Review 5.  Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  M M Buckley; R N Brogden; L B Barradell; K L Goa
Journal:  Drugs       Date:  1992-09       Impact factor: 9.546

6.  Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone.

Authors:  M R Visser; M Rozenberg-Arska; H Beumer; I M Hoepelman; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191
  6 in total
  3 in total

1.  Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Authors:  Y Carmeli; N Troillet; G M Eliopoulos; M H Samore
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients.

Authors:  Ray Y Hachem; Roy F Chemaly; Corine A Ahmar; Ying Jiang; Maha R Boktour; Georges Abou Rjaili; Gerald P Bodey; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

3.  Clinico-epidemiological profile of Acinetobacter and Pseudomonas infections, and their antibiotic-resistant pattern in a tertiary care center, Western Nepal.

Authors:  Shankar Baral; Anjila Pokharel; Supram Hosuru Subramanya; Niranjan Nayak
Journal:  Nepal J Epidemiol       Date:  2019-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.